$KDP

Keurig Dr Pepper Non-GAAP EPS of $0.66 beats by $0.04, revenue of $7.34B beats by $10M (KDP:NASDAQ)

Keurig Dr Pepper reported Q3 Non-GAAP EPS of $0.66, exceeding estimates by $0.04, with revenue of $7.34B, up 70.3% year-over-year. The company reaffirmed its FY2026 guidance, expecting net sales between $25.9B and $26.4B, slightly below consensus of $26.31B.

Original reporting
Published Nov 3, 2026, 12:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$KDP
Neutral
high confidence
Mentioned
$KDP
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$KDPNeutralHigh
01

Why it matters

The earnings beat supports short-term price appreciation, but reaffirmed guidance tempers expectations.

02

Market read

Earnings beat provides a fresh catalyst for traders; guidance suggests limited upside.

03

What to watch

Potential headwinds from input cost inflation could pressure margins.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

KDP released its Q3 2026 earnings, beating consensus on EPS and revenue.

Company-level read

Ticker impact

$KDPNeutralHigh confidence
Context

Q3 Non-GAAP EPS of $0.66 beats expectations by $0.04 and revenue of $7.34B beats by $10M; FY2026 guidance reaffirmed.

Expected impact

likely modest upside as market prices in the EPS beat, but guidance may cap further rally

Evidence & confidence

Beat on earnings and revenue provides positive catalyst; reaffirmed guidance signals no surprise downside.

Market effects

Soft drink and beverage sector may see slight lift from strong earnings.

U.S. consumer staples index could see modest gain.

Limited; primarily impacts U.S. markets.

Counterpoint

Guidance reaffirmation may indicate limited growth, suggesting caution despite beat.

Key entities

  • Keurig Dr Pepper

    Beverage and coffee company reporting Q3 results.

Related articles

$KDPMed

Keurig Dr Pepper Inc. Q3 2026 Earnings Call Summary

Keurig Dr Pepper Inc. reported Q3 2026 earnings, highlighting double-digit net sales growth in US refreshment beverages and a $1 billion milestone for Dr Pepper Zero Sugar. Energy drinks reached a 10% market share, while coffee performance was impacted by consumer shifts to lower-cost formats. The company reaffirmed low double-digit EPS growth for 2026 and confirmed plans to separate into two public companies by early 2027.

$KDPMedAI 8/10

Keurig Dr Pepper Q3 Earnings Call Highlights

Keurig Dr Pepper (KDP) reported Q3 earnings, highlighting 2.7% U.S. Coffee sales growth despite consumer value pressures. GHOST energy drink surpassed 10% market share, and Electrolit grew 40%. KDP launched the Keurig Alta system. JDE Peet's exceeded expectations, contributing $2.6B in net sales. KDP raised JDE Peet's EPS outlook but lowered legacy KDP growth expectations. The company plans to use $780M from asset sales for debt repayment and reaffirmed its 2026 sales outlook.

$KDPHighAI 9/10

Keurig Dr Pepper Reports Q3 Results and Reaffirms Guidance for 2026

Keurig Dr Pepper Inc. (KDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Keurig Dr Pepper Reports Q3 Results and Reaffirms Guidance for 2026 Drove Healthy Q3 Net Sales Momentum, with Growth Across all Legacy KDP Segments Delivered Q3 Diluted EPS Increase of More Than 20% FRISCO, TX and BURLINGTON, MA ( November 3, 2026 ) – Keurig Dr Peppe

$KDPHighAI 8/10

Why is Keurig Dr Pepper stock sliding today?

Keurig Dr Pepper (KDP) stock fell 3.9% in pre-market trading after Q3 2026 earnings beat estimates but showed margin compression and no guidance upgrade. Adjusted EPS was $0.66 vs. $0.62 estimate, and net sales were $7.34B vs. $7.33B estimate. The company reaffirmed full-year guidance, disappointing investors.